{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:58:40Z","timestamp":1791421120395,"version":"4.3.3"},"reference-count":163,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s11882-018-0764-z","type":"journal-article","created":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T01:45:48Z","timestamp":1519177548000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Cutaneous Manifestations of Reactions to Biologics"],"prefix":"10.1007","volume":"18","author":[{"given":"Iris M.","family":"Otani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleena","family":"Banerji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,21]]},"reference":[{"key":"764_CR1","unstructured":"Infliximab [package insert]. Janssen Biotech, Inc., Horsham, PA; November 2013. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/103772s5359lbl.pdf . Accessed 9 Dec 2017."},{"key":"764_CR2","unstructured":"Etanercept [package insert]. Immunex Corporation, Thousand Oaks, CA; December 2012. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/103795s5503lbl.pdf . Accessed 9 Dec 2017."},{"key":"764_CR3","unstructured":"Adalimumab [package insert]. AbbVie Inc., North Chicago, IL; October 2017. http:\/\/www.rxabbvie.com\/pdf\/humira.pdf . Accessed 10 Dec 2017."},{"key":"764_CR4","unstructured":"Certolizumab [package insert]. UCB, Inc., Smyrna, GA; January 2017. https:\/\/www.cimzia.com\/sites\/default\/files\/docs\/Prescribing_Information.pdf . Accessed 10 Dec 2017."},{"key":"764_CR5","unstructured":"Golimumab [package insert]. Janssen Biotech, Inc., Horsham, PA; June 2017. https:\/\/www.simponihcp.com\/shared\/product\/simponi\/prescribing-information.pdf . Accessed 10 Dec 2017."},{"key":"764_CR6","unstructured":"Anakinra [package insert]. Swedish Orphan Biovitrum AB, Stockholm, Sweden; May 2016. http:\/\/www.kineretrx.com\/pdf\/Full-Prescribing-Information-English.pdf . Accessed 10 Dec 2017."},{"key":"764_CR7","unstructured":"Rilonacept [package insert]. Regeneron Pharmaceuticals, Inc., Tarrytown, NY; September 2016. https:\/\/www.regeneron.com\/sites\/default\/files\/Arcalyst_FPI.pdf . Accessed 10 Dec 2017."},{"key":"764_CR8","unstructured":"Canakinumab [package insert]. Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; December 2016. https:\/\/www.pharma.us.novartis.com\/sites\/www.pharma.us.novartis.com\/files\/ilaris.pdf . Accessed 10 Dec 2017."},{"key":"764_CR9","unstructured":"Tocilizumab [package insert]. Genentech, Inc., South San Francisco, CA; August 2017. https:\/\/www.gene.com\/download\/pdf\/actemra_prescribing.pdf . Accessed 10 Dec 2017."},{"key":"764_CR10","unstructured":"Siltuximab [package insert]. Janssen Biotech, Inc., Horsham, PA; November 2015. https:\/\/www.sylvant.com\/sites\/www.sylvant.com\/files\/sylvant-prescribing-information.pdf . Accessed 10 Dec 2017."},{"key":"764_CR11","unstructured":"Rituximab [package insert]. Genentech, Inc., South San Francisco, CA; April 2016. https:\/\/www.gene.com\/download\/pdf\/rituxan_prescribing.pdf . Accessed 10 Dec 2017."},{"key":"764_CR12","unstructured":"Belimumab [package insert]. Human Genome Sciences, Inc., Rockville, MD; July 2017. https:\/\/www.gsksource.com\/pharma\/content\/dam\/GlaxoSmithKline\/US\/en\/Prescribing_Information\/Benlysta\/pdf\/BENLYSTA-PI-MG-IFU-COMBINED.PDF . Accessed 10 Dec 2017."},{"key":"764_CR13","unstructured":"Ustekinumab [package insert]. Janssen Biotech, Inc., Horsham, PA; September 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/761044lbl.pdf . Accessed 8 Oct 2017."},{"key":"764_CR14","unstructured":"Secukinumab [package insert]. Novartis Pharmaceuticals Corporation, East Hanover, NJ; September 2017. https:\/\/www.pharma.us.novartis.com\/sites\/www.pharma.us.novartis.com\/files\/cosentyx.pdf . Accessed 3 Dec 2017."},{"key":"764_CR15","unstructured":"Ixekizumab [package insert]. Eli Lilly and Company, Indianapolis, IN; March 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/125521s000lbl.pdf . Accessed 8 Oct 2017."},{"key":"764_CR16","unstructured":"Brodalumab [package insert]. Valeant Pharmaceuticals International, Inc., Luxembourg; February 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761032lbl.pdf . Accessed 8 Oct 2017."},{"key":"764_CR17","unstructured":"Nivolumab [package insert]. Bristol-Myers Squibb Company, Princeton, NJ; October 2017. https:\/\/packageinserts.bms.com\/pi\/pi_opdivo.pdf . Accessed 12 Oct 2017."},{"key":"764_CR18","unstructured":"Pembrolizumab [package insert]. Merck & Co., Inc., Whitehouse Station, NJ; November 2017. http:\/\/www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf . Accessed 12 Oct 2017."},{"key":"764_CR19","unstructured":"Avelumab [package insert]. EMD Serono, Inc., Rockland, MA; October 2017. http:\/\/www.emdserono.com\/ms.country.us\/en\/images\/Bavencio_PI_tcm115_161084.pdf?Version= . Accessed 12 Oct 2017."},{"key":"764_CR20","unstructured":"Atezolizumab [package insert]. Genentech, Inc., South San Francisco, CA; April 2017. https:\/\/www.gene.com\/download\/pdf\/tecentriq_prescribing.pdf . Accessed 3 Dec 2017."},{"key":"764_CR21","unstructured":"Durvalumab [package insert]. AstraZeneca UK Limited, Cambridge, England; April 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761069s000lbl.pdf . Accessed 12 Oct 2017."},{"key":"764_CR22","unstructured":"Ipilimumab [package insert]. Bristol-Myers Squibb Company, Princeton, NJ; October 2015. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125377s073lbl.pdf . Accessed 12 Oct 2017."},{"key":"764_CR23","unstructured":"Dupilumab [package insert]. Regeneron Pharmaceuticals, Inc., Tarrytown, NY; March 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761055lbl.pdf . Accessed 15 Oct 2017."},{"key":"764_CR24","unstructured":"Mepolizumab [package insert]. GlaxoSmithKline LLC, Philadelphia, PA\u00a0; November 2015. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125526Orig1s000Lbl.pdf . Accessed 15 Oct 2017."},{"issue":"18","key":"764_CR25","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1007\/s40265-015-0513-8","volume":"75","author":"GM Keating","year":"2015","unstructured":"Keating GM. Mepolizumab: First Global Approval. Drugs. 2015;75(18):2163\u20139. https:\/\/doi.org\/10.1007\/s40265-015-0513-8 .","journal-title":"Drugs"},{"issue":"5","key":"764_CR26","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/j.1398-9995.2005.00791.x","volume":"60","author":"JM Oldhoff","year":"2005","unstructured":"Oldhoff JM, Darsow U, Werfel T, Katzer K, Wulf A, Laifaoui J, et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy. 2005;60(5):693\u20136. https:\/\/doi.org\/10.1111\/j.1398-9995.2005.00791.x.","journal-title":"Allergy"},{"issue":"12","key":"764_CR27","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1056\/NEJMoa070812","volume":"358","author":"ME Rothenberg","year":"2008","unstructured":"Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008;358(12):1215\u201328. https:\/\/doi.org\/10.1056\/NEJMoa070812 .","journal-title":"N Engl J Med"},{"issue":"6","key":"764_CR28","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.jaci.2010.03.028","volume":"125","author":"S Kim","year":"2010","unstructured":"Kim S, Marigowda G, Oren E, Israel E, Wechsler ME. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol. 2010;125(6):1336\u201343. https:\/\/doi.org\/10.1016\/j.jaci.2010.03.028 .","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"764_CR29","doi-asserted-by":"publisher","first-page":"341","DOI":"10.7326\/0003-4819-155-5-201109060-00026","volume":"155","author":"F Moosig","year":"2011","unstructured":"Moosig F, Gross WL, Herrmann K, Bremer JP, Hellmich B. Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. Ann Intern Med. 2011;155(5):341\u20133. https:\/\/doi.org\/10.7326\/0003-4819-155-5-201109060-00026 .","journal-title":"Ann Intern Med"},{"issue":"20","key":"764_CR30","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","volume":"376","author":"ME Wechsler","year":"2017","unstructured":"Wechsler ME, Akuthota P, Jayne D, Khoury P, Klion A, Langford CA, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017;376(20):1921\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1702079 .","journal-title":"N Engl J Med"},{"issue":"5","key":"764_CR31","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jaci.2011.07.056","volume":"128","author":"P Gevaert","year":"2011","unstructured":"Gevaert P, Van Bruaene N, Cattaert T, van Steen K, van Zele T, Acke F, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol. 2011;128(5):989\u201395.e1-8. https:\/\/doi.org\/10.1016\/j.jaci.2011.07.056 .","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"764_CR32","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jaci.2006.05.031","volume":"118","author":"P Gevaert","year":"2006","unstructured":"Gevaert P, Lang-Loidolt D, Lackner A, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol. 2006;118(5):1133\u201341. https:\/\/doi.org\/10.1016\/j.jaci.2006.05.031.","journal-title":"J Allergy Clin Immunol"},{"key":"764_CR33","unstructured":"Reslizumab [package insert]. Teva Respiratory, LLC Frazer, PA; March 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/761033lbl.pdf . Accessed 15 Oct 2017."},{"key":"764_CR34","unstructured":"Tofacitinib [package insert]. Pfizer Inc., NY, NY; August 2017. http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=959 . Accessed 10 Dec 2017."},{"key":"764_CR35","unstructured":"Hodge JA, Kawabata TT, Krishnaswami S, et al. The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 34(2):318\u201328. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26966791 . Accessed 10 Dec 2017"},{"issue":"5","key":"764_CR36","doi-asserted-by":"publisher","first-page":"837","DOI":"10.3899\/jrheum.130683","volume":"41","author":"J Wollenhaupt","year":"2014","unstructured":"Wollenhaupt J, Silverfield J, Lee EB, Curtis JR, Wood SP, Soma K, et al. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol. 2014;41(5):837\u201352. https:\/\/doi.org\/10.3899\/jrheum.130683.","journal-title":"J Rheumatol"},{"key":"764_CR37","doi-asserted-by":"publisher","unstructured":"Liu LY, Craiglow BG, King BA. Tofacitinib 2% ointment, a topical janus kinase inhibitor, for the treatment of alopecia areata: a pilot study of 10 patients. J Am Acad Dermatol. 2017; https:\/\/doi.org\/10.1016\/j.jaad.2017.10.043 .","DOI":"10.1016\/j.jaad.2017.10.043"},{"issue":"5","key":"764_CR38","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1056\/NEJMc1707500","volume":"377","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Panes J. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;377(5):496\u20137. https:\/\/doi.org\/10.1056\/NEJMc1707500 .","journal-title":"N Engl J Med"},{"key":"764_CR39","unstructured":"Abatacept [package insert]. Bristol-Myers Squibb Company, Princeton, NJ; June 2017. https:\/\/packageinserts.bms.com\/pi\/pi_orencia.pdf . Accessed 3 Dec 2017."},{"issue":"2","key":"764_CR40","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1136\/ard.2006.057018","volume":"66","author":"AS Russell","year":"2007","unstructured":"Russell AS, Wallenstein GV, Li T, Martin MC, Maclean R, Blaisdell B, et al. Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment. Ann Rheum Dis. 2007;66(2):189\u201394. https:\/\/doi.org\/10.1136\/ard.2006.057018.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"764_CR41","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s40265-017-0775-4","volume":"77","author":"HA Blair","year":"2017","unstructured":"Blair HA, Deeks ED. Abatacept: a review in rheumatoid arthritis. Drugs. 2017;77(11):1221\u201333. https:\/\/doi.org\/10.1007\/s40265-017-0775-4 .","journal-title":"Drugs"},{"issue":"10","key":"764_CR42","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1002\/art.39234","volume":"67","author":"DJ Lovell","year":"2015","unstructured":"Lovell DJ, Ruperto N, Mouy R, Paz E, Rubio-P\u00e9rez N, Silva CA, et al. Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years. Arthritis Rheumatol (Hoboken, NJ). 2015;67(10):2759\u201370. https:\/\/doi.org\/10.1002\/art.39234 .","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"issue":"4","key":"764_CR43","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/art.30176","volume":"63","author":"P Mease","year":"2011","unstructured":"Mease P, Genovese MC, Gladstein G, Kivitz AJ, Ritchlin C, Tak PP, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum. 2011;63(4):939\u201348. https:\/\/doi.org\/10.1002\/art.30176 .","journal-title":"Arthritis Rheum"},{"issue":"9","key":"764_CR44","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, Gottlieb AB, van der Heijde D, FitzGerald O, Johnsen A, Nys M, et al. Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis. 2017;76(9):1550\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210724.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"764_CR45","doi-asserted-by":"publisher","first-page":"362","DOI":"10.2340\/00015555-1042","volume":"91","author":"K Kato","year":"2011","unstructured":"Kato K, Satoh T, Nishizawa A, Yokozeki H. Psoriasiform drug eruption due to abatacept. Acta Derm Venereol. 2011;91(3):362\u20133. https:\/\/doi.org\/10.2340\/00015555-1042 .","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"764_CR46","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2147\/tcrm.2007.3.2.259","volume":"3","author":"M Hutchinson","year":"2007","unstructured":"Hutchinson M. Natalizumab: a new treatment for relapsing remitting multiple sclerosis. Ther Clin Risk Manag. 2007;3(2):259\u201368. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18360634 . Accessed 3 Dec 2017","journal-title":"Ther Clin Risk Manag"},{"key":"764_CR47","unstructured":"Vedolizumab [package insert]. Takeda Pharmaceuticals America, Inc., Deerfield, IL; May 2014. http:\/\/general.takedapharm.com\/content\/file.aspx?filetypecode=ENTYVIOPI&cacheRandomizer=01eae758-4130-43ee-b586-2c3763f66682 ."},{"issue":"8","key":"764_CR48","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","volume":"369","author":"WJ Sandborn","year":"2013","unstructured":"Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2013;369(8):711\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1215739 .","journal-title":"N Engl J Med"},{"issue":"1","key":"764_CR49","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/ibd.20014","volume":"13","author":"BE Sands","year":"2007","unstructured":"Sands BE, Kozarek R, Spainhour J, Barish CF, Becker S, Goldberg L, et al. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn\u2019s disease not in remission while receiving infliximab. Inflamm Bowel Dis. 2007;13(1):2\u201311. https:\/\/doi.org\/10.1002\/ibd.20014.","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"764_CR50","doi-asserted-by":"publisher","first-page":"jjw177","DOI":"10.1093\/ecco-jcc\/jjw177","volume":"11","author":"EV Loftus","year":"2016","unstructured":"Loftus EV, Colombel J-F, Feagan BG, et al. Long-term efficacy of vedolizumab for ulcerative colitis. J Crohn's Colitis. 2016;11(4):jjw177. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjw177 .","journal-title":"J Crohn's Colitis"},{"issue":"8","key":"764_CR51","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/ibd.21896","volume":"18","author":"A Parikh","year":"2012","unstructured":"Parikh A, Leach T, Wyant T, Scholz C, Sankoh S, Mould DR, et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis. 2012;18(8):1470\u20139. https:\/\/doi.org\/10.1002\/ibd.21896.","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"764_CR52","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/apt.12639","volume":"39","author":"T Lobat\u00f3n","year":"2014","unstructured":"Lobat\u00f3n T, Vermeire S, Van Assche G, Rutgeerts P. Review article: anti-adhesion therapies for inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39(6):579\u201394. https:\/\/doi.org\/10.1111\/apt.12639 .","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"764_CR53","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/ajg.2015.205","volume":"110","author":"E Fr\u00e9ling","year":"2015","unstructured":"\u2022 Fr\u00e9ling E, Baumann C, Cuny J-F, Bigard MA, Schmutz JL, Barbaud A, et al. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience. Am J Gastroenterol. 2015;110(8):1186\u201396. https:\/\/doi.org\/10.1038\/ajg.2015.205 . A study describing cutaneous manifestations in 583 patients with IBD treated with anti-TNF therapy over a 14-year period.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"764_CR54","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1159\/000338691","volume":"224","author":"V Failla","year":"2012","unstructured":"Failla V, Jacques J, Castronovo C, Nikkels AF. Herpes zoster in patients treated with biologicals. Dermatology. 2012;224(3):251\u20136. https:\/\/doi.org\/10.1159\/000338691 .","journal-title":"Dermatology"},{"issue":"3 Pt 1","key":"764_CR55","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/jid.2011.383","volume":"132","author":"G Serac","year":"2012","unstructured":"Serac G, Tubach F, Mariette X, Salmon-C\u00e9ron D, Ravaud P, Liot\u00e9 F, et al. Risk of herpes zoster in patients receiving anti-TNF-\u03b1 in the prospective French RATIO registry. J Investig Dermatol. 2012;132(3 Pt 1):726\u20139. https:\/\/doi.org\/10.1038\/jid.2011.383.","journal-title":"J Investig Dermatol"},{"issue":"7","key":"764_CR56","doi-asserted-by":"publisher","first-page":"717","DOI":"10.2217\/imt.15.45","volume":"7","author":"N Ibis","year":"2015","unstructured":"Ibis N, Hocaoglu S, Cebicci MA, Sutbeyaz ST, Calis HT. Palmoplantar pustular psoriasis induced by adalimumab: a case report and literature review. Immunotherapy. 2015;7(7):717\u201320. https:\/\/doi.org\/10.2217\/imt.15.45 .","journal-title":"Immunotherapy"},{"issue":"6","key":"764_CR57","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1111\/bjd.13146","volume":"171","author":"P Jayasekera","year":"2014","unstructured":"Jayasekera P, Parslew R, Al-Sharqi A. A case of tumour necrosis factor-\u03b1 inhibitor- and rituximab-induced plantar pustular psoriasis that completely resolved with tocilizumab. Br J Dermatol. 2014;171(6):1546\u20139. https:\/\/doi.org\/10.1111\/bjd.13146 .","journal-title":"Br J Dermatol"},{"issue":"1","key":"764_CR58","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s10384-012-0198-4","volume":"57","author":"Y Kawazoe","year":"2013","unstructured":"Kawazoe Y, Sugita S, Yamada Y, Akino A, Miura K, Mochizuki M. Psoriasis triggered by infliximab in a patient with Beh\u00e7et\u2019s disease. Jpn J Ophthalmol. 2013;57(1):95\u20137. https:\/\/doi.org\/10.1007\/s10384-012-0198-4 .","journal-title":"Jpn J Ophthalmol"},{"issue":"6","key":"764_CR59","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.crohns.2013.10.013","volume":"8","author":"A Afzali","year":"2014","unstructured":"Afzali A, Wheat CL, Hu JK, Olerud JE, Lee SD. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series. J Crohns Colitis. 2014;8(6):480\u20138. https:\/\/doi.org\/10.1016\/j.crohns.2013.10.013 .","journal-title":"J Crohns Colitis"},{"issue":"2","key":"764_CR60","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jaad.2016.08.012","volume":"76","author":"G Brown","year":"2017","unstructured":"\u2022 Brown G, Wang E, Leon A, Huynh M, Wehner M, Matro R, et al. Tumor necrosis factor-\u03b1 inhibitor-induced psoriasis: systematic review of clinical features, histopathological findings, and management experience. J Am Acad Dermatol. 2017;76(2):334\u201341. https:\/\/doi.org\/10.1016\/j.jaad.2016.08.012 . A review of 216 published cases of new-onset psoriasis attributed to anti-TNF therapy.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"764_CR61","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1053\/j.gastro.2012.05.004","volume":"143","author":"MD Long","year":"2012","unstructured":"Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012;143(2):390\u2013399.e1. https:\/\/doi.org\/10.1053\/j.gastro.2012.05.004 .","journal-title":"Gastroenterology"},{"issue":"10","key":"764_CR62","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/nrrheum.2014.123","volume":"10","author":"O Boyman","year":"2014","unstructured":"Boyman O, Comte D, Spertini F. Adverse reactions to biologic agents and their medical management. Nat Rev Rheumatol. 2014;10(10):612\u201327. https:\/\/doi.org\/10.1038\/nrrheum.2014.123 .","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"764_CR63","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1177\/0961203313517153","volume":"23","author":"AMG Brunasso","year":"2014","unstructured":"Brunasso AMG, Aberer W, Massone C. Subacute lupus erythematosus during treatment with golimumab for seronegative rheumatoid arthritis. Lupus. 2014;23(2):201\u20133. https:\/\/doi.org\/10.1177\/0961203313517153 .","journal-title":"Lupus"},{"issue":"8","key":"764_CR64","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.mayocp.2012.04.011","volume":"87","author":"O Sokumbi","year":"2012","unstructured":"Sokumbi O, Wetter DA, Makol A, Warrington KJ. Vasculitis associated with tumor necrosis factor-\u03b1 inhibitors. Mayo Clin Proc. 2012;87(8):739\u201345. https:\/\/doi.org\/10.1016\/j.mayocp.2012.04.011 .","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"764_CR65","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1001\/jamadermatol.2013.5220","volume":"149","author":"SW Liu","year":"2013","unstructured":"Liu SW, Velez NF, Lam C, Femia A, Granter SR, Townsend HB, et al. Dermatomyositis induced by anti-tumor necrosis factor in a patient with juvenile idiopathic arthritis. JAMA Dermatol. 2013;149(10):1204\u20138. https:\/\/doi.org\/10.1001\/jamadermatol.2013.5220 .","journal-title":"JAMA Dermatol"},{"issue":"3","key":"764_CR66","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1159\/000318008","volume":"221","author":"L Boussemart","year":"2010","unstructured":"Boussemart L, Jacobelli S, Batteux F, Goulvestre C, Grange P, Carlotti A, et al. Autoimmune bullous skin diseases occurring under anti-tumor necrosis factor therapy: two case reports. Dermatology. 2010;221(3):201\u20135. https:\/\/doi.org\/10.1159\/000318008.","journal-title":"Dermatology"},{"issue":"6","key":"764_CR67","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jdcr.2016.09.002","volume":"2","author":"KD Bryant","year":"2016","unstructured":"Bryant KD, DeNunzio MJ, Ford MJ. Linear IgA dermatosis after infliximab infusion for ulcerative colitis. JAAD Case Rep. 2016;2(6):448\u201350. https:\/\/doi.org\/10.1016\/j.jdcr.2016.09.002 .","journal-title":"JAAD Case Rep"},{"issue":"2","key":"764_CR68","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1159\/000431172","volume":"231","author":"J Hoffmann","year":"2015","unstructured":"Hoffmann J, Hadaschik E, Enk A, Stremmel W, Gauss A. Linear IgA bullous dermatosis secondary to infliximab therapy in a patient with ulcerative colitis. Dermatology. 2015;231(2):112\u20135. https:\/\/doi.org\/10.1159\/000431172 .","journal-title":"Dermatology"},{"issue":"5","key":"764_CR69","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/j.1600-0560.2012.01894.x","volume":"39","author":"EB Hawryluk","year":"2012","unstructured":"Hawryluk EB, Linskey KR, Duncan LM, Nazarian RM. Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists. J Cutan Pathol. 2012;39(5):481\u201392. https:\/\/doi.org\/10.1111\/j.1600-0560.2012.01894.x .","journal-title":"J Cutan Pathol"},{"issue":"4","key":"764_CR70","doi-asserted-by":"publisher","first-page":"602","DOI":"10.3109\/s10165-011-0550-4","volume":"22","author":"J Ram\u00edrez","year":"2012","unstructured":"Ram\u00edrez J, Hern\u00e1ndez MV, Galve J, Ca\u00f1ete JD, Sanmart\u00ed R. Morphea associated with the use of adalimumab: a case report and review of the literature. Mod Rheumatol. 2012;22(4):602\u20134. https:\/\/doi.org\/10.1007\/s10165-011-0550-4 .","journal-title":"Mod Rheumatol"},{"issue":"1","key":"764_CR71","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/rheumatology\/ker322","volume":"51","author":"N Tugnet","year":"2012","unstructured":"Tugnet N, Youssef A, Whallett AJ. Wells\u2019 syndrome (eosinophilic cellulitis) secondary to infliximab. Rheumatology (Oxford). 2012;51(1):195\u20136. https:\/\/doi.org\/10.1093\/rheumatology\/ker322 .","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"764_CR72","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1136\/ard.2005.044685","volume":"65","author":"P Boura","year":"2006","unstructured":"Boura P, Sarantopoulos A, Lefaki I, Skendros P, Papadopoulos P. Eosinophilic cellulitis (Wells\u2019 syndrome) as a cutaneous reaction to the administration of adalimumab. Ann Rheum Dis. 2006;65(6):839\u201340. https:\/\/doi.org\/10.1136\/ard.2005.044685 .","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"764_CR73","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1001\/archderm.142.2.218","volume":"142","author":"H Winfield","year":"2006","unstructured":"Winfield H, Lain E, Horn T, Hoskyn J. Eosinophilic cellulitislike reaction to subcutaneous etanercept injection. Arch Dermatol. 2006;142(2):218\u201320. https:\/\/doi.org\/10.1001\/archderm.142.2.218.","journal-title":"Arch Dermatol"},{"issue":"8","key":"764_CR74","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.3899\/jrheum.110956","volume":"39","author":"J Kelsall","year":"2012","unstructured":"Kelsall J, Rogers P, Galindo G, De Vera MA. Safety of infliximab treatment in patients with rheumatoid arthritis in a real-world clinical setting: description and evaluation of infusion reactions. J Rheumatol. 2012;39(8):1539\u201345. https:\/\/doi.org\/10.3899\/jrheum.110956 .","journal-title":"J Rheumatol"},{"issue":"10","key":"764_CR75","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.crohns.2013.01.009","volume":"7","author":"G Mocci","year":"2013","unstructured":"Mocci G, Marzo M, Papa A, Armuzzi A, Guidi L. Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease. J Crohns Colitis. 2013;7(10):769\u201379. https:\/\/doi.org\/10.1016\/j.crohns.2013.01.009 .","journal-title":"J Crohns Colitis"},{"issue":"18","key":"764_CR76","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1001\/jama.2016.15826","volume":"316","author":"A Brucato","year":"2016","unstructured":"Brucato A, Imazio M, Gattorno M, Lazaros G, Maestroni S, Carraro M, et al. Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: the AIRTRIP randomized clinical trial. JAMA. 2016;316(18):1906\u201312. https:\/\/doi.org\/10.1001\/jama.2016.15826 .","journal-title":"JAMA"},{"issue":"8","key":"764_CR77","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1093\/rheumatology\/kew208","volume":"55","author":"T Kullenberg","year":"2016","unstructured":"Kullenberg T, L\u00f6fqvist M, Leinonen M, Goldbach-Mansky R, Olivecrona H. Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes. Rheumatology (Oxford). 2016;55(8):1499\u2013506. https:\/\/doi.org\/10.1093\/rheumatology\/kew208 .","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"764_CR78","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.amjcard.2015.07.047","volume":"116","author":"S Jain","year":"2015","unstructured":"Jain S, Thongprayoon C, Espinosa RE, Hayes SN, Klarich KW, Cooper LT, et al. Effectiveness and safety of anakinra for management of refractory pericarditis. Am J Cardiol. 2015;116(8):1277\u20139. https:\/\/doi.org\/10.1016\/j.amjcard.2015.07.047.","journal-title":"Am J Cardiol"},{"issue":"39","key":"764_CR79","doi-asserted-by":"publisher","first-page":"e1554","DOI":"10.1097\/MD.0000000000001554","volume":"94","author":"F Ortiz-Sanju\u00e1n","year":"2015","unstructured":"Ortiz-Sanju\u00e1n F, Blanco R, Riancho-Zarrabeitia L, Casta\u00f1eda S, Oliv\u00e9 A, Riveros A, et al. Efficacy of anakinra in refractory adult-onset Still\u2019s disease: multicenter study of 41 patients and literature review. Medicine (Baltimore). 2015;94(39):e1554. https:\/\/doi.org\/10.1097\/MD.0000000000001554.","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"764_CR80","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.3899\/jrheum.111549","volume":"39","author":"D Nordstr\u00f6m","year":"2012","unstructured":"Nordstr\u00f6m D, Knight A, Luukkainen R, et al. Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still\u2019s disease. An open, randomized, multicenter study. J Rheumatol. 2012;39(10):2008\u201311. https:\/\/doi.org\/10.3899\/jrheum.111549 .","journal-title":"J Rheumatol"},{"issue":"1","key":"764_CR81","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1001\/jamadermatol.2015.3903","volume":"152","author":"V Tzanetakou","year":"2016","unstructured":"Tzanetakou V, Kanni T, Giatrakou S, Katoulis A, Papadavid E, Netea MG, et al. Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial. JAMA Dermatol. 2016;152(1):52\u20139. https:\/\/doi.org\/10.1001\/jamadermatol.2015.3903.","journal-title":"JAMA Dermatol"},{"issue":"8","key":"764_CR82","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.3899\/jrheum.131226","volume":"41","author":"JS Sundy","year":"2014","unstructured":"Sundy JS, Schumacher HR, Kivitz A, Weinstein SP, Wu R, King-Davis S, et al. Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study. J Rheumatol. 2014;41(8):1703\u201311. https:\/\/doi.org\/10.3899\/jrheum.131226 .","journal-title":"J Rheumatol"},{"issue":"8","key":"764_CR83","doi-asserted-by":"publisher","first-page":"533","DOI":"10.7326\/0003-4819-157-8-201210160-00003","volume":"157","author":"PJ Hashkes","year":"2012","unstructured":"Hashkes PJ, Spalding SJ, Giannini EH, Huang B, Johnson A, Park G, et al. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever. Ann Intern Med. 2012;157(8):533\u201341. https:\/\/doi.org\/10.7326\/0003-4819-157-8-201210160-00003 .","journal-title":"Ann Intern Med"},{"issue":"10","key":"764_CR84","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1016\/j.clinthera.2012.09.009","volume":"34","author":"HM Hoffman","year":"2012","unstructured":"Hoffman HM, Throne ML, Amar NJ, Cartwright RC, Kivitz AJ, Soo Y, et al. Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study. Clin Ther. 2012;34(10):2091\u2013103. https:\/\/doi.org\/10.1016\/j.clinthera.2012.09.009 .","journal-title":"Clin Ther"},{"issue":"1","key":"764_CR85","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1136\/annrheumdis-2015-209031","volume":"76","author":"M Gattorno","year":"2017","unstructured":"Gattorno M, Obici L, Cattalini M, Tormey V, Abrams K, Davis N, et al. Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study. Ann Rheum Dis. 2017;76(1):173\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2015-209031.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"764_CR86","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1093\/rheumatology\/kev416","volume":"55","author":"JB Kuemmerle-Deschner","year":"2016","unstructured":"Kuemmerle-Deschner JB, Hofer F, Endres T, Kortus-Goetze B, Blank N, Wei\u00dfbarth-Riedel E, et al. Real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome. Rheumatology. 2016;55(4):689\u201396. https:\/\/doi.org\/10.1093\/rheumatology\/kev416.","journal-title":"Rheumatology"},{"issue":"1","key":"764_CR87","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s13075-015-0765-4","volume":"17","author":"A G\u00fcl","year":"2015","unstructured":"G\u00fcl A, Ozdogan H, Erer B, Ugurlu S, Kasapcopur O, Davis N, et al. Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever. Arthritis Res Ther. 2015;17(1):243. https:\/\/doi.org\/10.1186\/s13075-015-0765-4.","journal-title":"Arthritis Res Ther"},{"issue":"15","key":"764_CR88","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1056\/NEJMc1711031","volume":"377","author":"M Akiyama","year":"2017","unstructured":"Akiyama M. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377(15):1493\u20135. https:\/\/doi.org\/10.1056\/NEJMc1711031 .","journal-title":"N Engl J Med"},{"issue":"10038","key":"764_CR89","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","volume":"387","author":"D Khanna","year":"2016","unstructured":"Khanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016;387(10038):2630\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(16)00232-4 .","journal-title":"Lancet"},{"issue":"4","key":"764_CR90","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1159\/000362266","volume":"228","author":"N Palmou-Fontana","year":"2014","unstructured":"Palmou-Fontana N, S\u00e1nchez Gavi\u00f1o JA, McGonagle D, Garc\u00eda-Martinez E, I\u00f1iguez de Onzo\u00f1o Mart\u00edn L. Tocilizumab-induced psoriasiform rash in rheumatoid arthritis. Dermatology. 2014;228(4):311\u20133. https:\/\/doi.org\/10.1159\/000362266.","journal-title":"Dermatology"},{"issue":"3","key":"764_CR91","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3899\/jrheum.111166","volume":"39","author":"D Wendling","year":"2012","unstructured":"Wendling D, Letho-Gyselinck H, Guillot X, Prati C. Psoriasis onset with tocilizumab treatment for rheumatoid arthritis. J Rheumatol. 2012;39(3):657. https:\/\/doi.org\/10.3899\/jrheum.111166 .","journal-title":"J Rheumatol"},{"key":"764_CR92","doi-asserted-by":"publisher","first-page":"517424","DOI":"10.1155\/2012\/517424.","volume":"2012","author":"JH Izquierdo","year":"2012","unstructured":"Izquierdo JH, Bonilla-Abad\u00eda F, Ochoa CD, Agualimpia A, Tob\u00f3n GJ, Ca\u00f1as CA. Acute generalized exanthematous pustulosis due to tocilizumab in a rheumatoid arthritis patient. Case Rep Rheumatol. 2012;2012:517424. https:\/\/doi.org\/10.1155\/2012\/517424.","journal-title":"Case Rep Rheumatol"},{"issue":"8","key":"764_CR93","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1093\/rheumatology\/keu181","volume":"53","author":"V Rocchi","year":"2014","unstructured":"Rocchi V, Puxeddu I, Cataldo G, del Corso I, Tavoni A, Bazzichi L, et al. Hypersensitivity reactions to tocilizumab: role of skin tests in diagnosis. Rheumatology (Oxford). 2014;53(8):1527\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/keu181.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"764_CR94","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1136\/annrheumdis-2013-203559","volume":"73","author":"J Sieper","year":"2014","unstructured":"Sieper J, Porter-Brown B, Thompson L, Harari O, Dougados M. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis. 2014;73(1):95\u2013100. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203559 .","journal-title":"Ann Rheum Dis"},{"issue":"30","key":"764_CR95","doi-asserted-by":"publisher","first-page":"30408","DOI":"10.18632\/oncotarget.4655.","volume":"6","author":"F Rhee van","year":"2015","unstructured":"van Rhee F, Casper C, Voorhees PM, Fayad LE, van de Velde H, Vermeulen J, et al. A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease. Oncotarget. 2015;6(30):30408\u201319. https:\/\/doi.org\/10.18632\/oncotarget.4655.","journal-title":"Oncotarget"},{"issue":"5","key":"764_CR96","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1158\/1078-0432.CCR-14-1678","volume":"21","author":"A Deisseroth","year":"2015","unstructured":"Deisseroth A, Ko C-W, Nie L, Zirkelbach JF, Zhao L, Bullock J, et al. FDA approval: Siltuximab for the treatment of patients with multicentric Castleman disease. Clin Cancer Res. 2015;21(5):950\u20134. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-1678 .","journal-title":"Clin Cancer Res"},{"issue":"6","key":"764_CR97","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.jaip.2017.08.004","volume":"5","author":"JT Wong","year":"2017","unstructured":"Wong JT, Long A. Rituximab hypersensitivity: evaluation, desensitization, and potential mechanisms. J Allergy Clin Immunol Pract. 2017;5(6):1564\u201371. https:\/\/doi.org\/10.1016\/j.jaip.2017.08.004 .","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"764_CR98","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jaip.2016.06.022","volume":"5","author":"AS Levin","year":"2017","unstructured":"\u2022 Levin AS, Otani IM, Lax T, Hochberg E, Banerji A. Reactions to rituximab in an outpatient infusion center: a 5-year review. J Allergy Clin Immunol Pract. 2017;5(1):107\u2013113.e1. https:\/\/doi.org\/10.1016\/j.jaip.2016.06.022 . A 5-year study of 67 patients with rituximab infusion reactions.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"22","key":"764_CR99","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1182\/blood-2014-06-582346","volume":"124","author":"M Khellaf","year":"2014","unstructured":"Khellaf M, Charles-Nelson A, Fain O, Terriou L, Viallard JF, Cheze S, et al. Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood. 2014;124(22):3228\u201336. https:\/\/doi.org\/10.1182\/blood-2014-06-582346.","journal-title":"Blood"},{"issue":"2","key":"764_CR100","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/bjh.13029","volume":"167","author":"H Tran","year":"2014","unstructured":"Tran H, Brighton T, Grigg A, McRae S, Dixon J, Thurley D, et al. A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study). Br J Haematol. 2014;167(2):243\u201351. https:\/\/doi.org\/10.1111\/bjh.13029.","journal-title":"Br J Haematol"},{"issue":"3","key":"764_CR101","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.semarthrit.2015.06.014","volume":"45","author":"P Karmacharya","year":"2015","unstructured":"Karmacharya P, Poudel DR, Pathak R, Donato AA, Ghimire S, Giri S, et al. Rituximab-induced serum sickness: a systematic review. Semin Arthritis Rheum. 2015;45(3):334\u201340. https:\/\/doi.org\/10.1016\/j.semarthrit.2015.06.014 .","journal-title":"Semin Arthritis Rheum"},{"issue":"20","key":"764_CR102","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1212\/WNL.0000000000003331","volume":"87","author":"J Salzer","year":"2016","unstructured":"Salzer J, Svenningsson R, Alping P, Novakova L, Bj\u00f6rck A, Fink K, et al. Rituximab in multiple sclerosis. Neurology. 2016;87(20):2074\u201381. https:\/\/doi.org\/10.1212\/WNL.0000000000003331.","journal-title":"Neurology"},{"key":"764_CR103","doi-asserted-by":"publisher","unstructured":"Laccarino L, Andreoli L, Bocci EB, et al. Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. J Autoimmun. 2017; https:\/\/doi.org\/10.1016\/j.jaut.2017.09.004 .","DOI":"10.1016\/j.jaut.2017.09.004"},{"issue":"5","key":"764_CR104","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/art.40049","volume":"69","author":"W Stohl","year":"2017","unstructured":"Stohl W, Schwarting A, Okada M, Scheinberg M, Doria A, Hammer AE, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol. 2017;69(5):1016\u201327. https:\/\/doi.org\/10.1002\/art.40049.","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"764_CR105","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3899\/jrheum.120886","volume":"40","author":"W Stohl","year":"2013","unstructured":"Stohl W, Merrill JT, McKay JD, Lisse JR, Zhong ZJ, Freimuth WW, et al. Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging study. J Rheumatol. 2013;40(5):579\u201389. https:\/\/doi.org\/10.3899\/jrheum.120886 .","journal-title":"J Rheumatol"},{"issue":"6","key":"764_CR106","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1111\/j.0022-202X.2004.23448.x","volume":"123","author":"CL Kauffman","year":"2004","unstructured":"Kauffman CL, Aria N, Toichi E, McCormick TS, Cooper KD, Gottlieb AB, et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Investig Dermatol. 2004;123(6):1037\u201344. https:\/\/doi.org\/10.1111\/j.0022-202X.2004.23448.x.","journal-title":"J Investig Dermatol"},{"issue":"6","key":"764_CR107","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJMoa062382","volume":"356","author":"GG Krueger","year":"2007","unstructured":"Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, et al. A human interleukin-12\/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007;356(6):580\u201392. https:\/\/doi.org\/10.1056\/NEJMoa062382 .","journal-title":"N Engl J Med"},{"issue":"9894","key":"764_CR108","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","volume":"382","author":"MI IB","year":"2013","unstructured":"IB MI, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet (London, England). 2013;382(9894):780\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(13)60594-2.","journal-title":"Lancet (London, England)."},{"issue":"4","key":"764_CR109","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1084\/jem.178.4.1223","volume":"178","author":"MJ Brunda","year":"1993","unstructured":"Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med. 1993;178(4):1223\u201330. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8104230 . Accessed 3 Dec 2017","journal-title":"J Exp Med"},{"issue":"6","key":"764_CR110","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1158\/0008-5472.CAN-05-3614","volume":"66","author":"A Maeda","year":"2006","unstructured":"Maeda A, Schneider SW, Kojima M, Beissert S, Schwarz T, Schwarz A. Enhanced photocarcinogenesis in interleukin-12-deficient mice. Cancer Res. 2006;66(6):2962\u20139. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-3614 .","journal-title":"Cancer Res"},{"issue":"7101","key":"764_CR111","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nature04808","volume":"442","author":"JL Langowski","year":"2006","unstructured":"Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, et al. IL-23 promotes tumour incidence and growth. Nature. 2006;442(7101):461\u20135. https:\/\/doi.org\/10.1038\/nature04808 .","journal-title":"Nature"},{"issue":"6","key":"764_CR112","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1080\/14740338.2017.1323864","volume":"16","author":"A L\u00f3pez-Ferrer","year":"2017","unstructured":"L\u00f3pez-Ferrer A, Laiz A, Puig L. The safety of ustekinumab for the treatment of psoriatic arthritis. Expert Opin Drug Saf. 2017;16(6):733\u201342. https:\/\/doi.org\/10.1080\/14740338.2017.1323864 .","journal-title":"Expert Opin Drug Saf"},{"key":"764_CR113","unstructured":"Translated. Ustekinumab: cutaneous disorders, malignancies, infections. Prescrire Int. 2015;24(156):17. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25729825 . Accessed 3 Dec 2017."},{"issue":"9625","key":"764_CR114","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","volume":"371","author":"CL Leonardi","year":"2008","unstructured":"Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet (London, England). 2008;371(9625):1665\u201374. https:\/\/doi.org\/10.1016\/S0140-6736(08)60725-4 .","journal-title":"Lancet (London, England)."},{"issue":"9625","key":"764_CR115","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","volume":"371","author":"KA Papp","year":"2008","unstructured":"Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet (London, England). 2008;371(9625):1675\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(08)60726-6 .","journal-title":"Lancet (London, England)."},{"issue":"5","key":"764_CR116","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.jaad.2011.06.011","volume":"66","author":"M Lebwohl","year":"2012","unstructured":"\u2022 Lebwohl M, Leonardi C, Griffiths CEM, Prinz JC, Szapary PO, Yeilding N, et al. Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (part I of II): results from analyses of general safety parameters from pooled phase 2 and 3 clinical trials. J Am Acad Dermatol. 2012;66(5):731\u201341. https:\/\/doi.org\/10.1016\/j.jaad.2011.06.011 . Pooled safety data from one Phase 2 and three Phase 3 trials (PHOENIX 1, PHOENIX 2, and ACCEPT) of 1247 patients treated for \u2265 two years.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"764_CR117","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1111\/bjd.13469","volume":"172","author":"RG Langley","year":"2015","unstructured":"\u2022 Langley RG, Lebwohl M, Krueger GG, Szapary PO, Wasfi Y, Chan D, et al. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. Br J Dermatol. 2015;172(5):1371\u201383. https:\/\/doi.org\/10.1111\/bjd.13469 . A 5-year follow-up efficacy and safety study of patients in the PHOENIX 2 clinical trial.","journal-title":"Br J Dermatol"},{"issue":"4","key":"764_CR118","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/bjd.12214","volume":"168","author":"KA Papp","year":"2013","unstructured":"\u2022 Papp KA, Griffiths CEM, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013;168(4):844\u201354. https:\/\/doi.org\/10.1111\/bjd.12214 . Safety analysis of 3117 patients with moderate-to-severe psoriasis who received more than one dose of ustekinumab, with 1482 patients receiving ustekinumab for \u2265 four years.","journal-title":"Br J Dermatol"},{"issue":"3","key":"764_CR119","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3109\/09546634.2010.534430","volume":"23","author":"KS Wenk","year":"2012","unstructured":"Wenk KS, Claros JM, Ehrlich A. Flare of pustular psoriasis after initiating ustekinumab therapy. J Dermatolog Treat. 2012;23(3):212\u20134. https:\/\/doi.org\/10.3109\/09546634.2010.534430 .","journal-title":"J Dermatolog Treat"},{"issue":"12","key":"764_CR120","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1001\/jamadermatol.2013.5728","volume":"149","author":"EF Stamell","year":"2013","unstructured":"Stamell EF, Kutner A, Viola K, Cohen SR. Ustekinumab associated with flares of psoriatic arthritis. JAMA Dermatol. 2013;149(12):1410\u20133. https:\/\/doi.org\/10.1001\/jamadermatol.2013.5728 .","journal-title":"JAMA Dermatol"},{"issue":"7","key":"764_CR121","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5070\/D34G31C0TM","volume":"18","author":"C Verros","year":"2012","unstructured":"Verros C, Rallis E, Crowe M. Letter: Alopecia areata during ustekinumab administration: co-existence or an adverse reaction? Dermatol Online J. 2012;18(7):14. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22863636 . Accessed 3 Dec 2017","journal-title":"Dermatol Online J"},{"issue":"4","key":"764_CR122","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.1016\/j.jaad.2011.11.955","volume":"67","author":"JG Becker","year":"2012","unstructured":"Becker JG, Mundi JP, Newlove T, Mones J, Shupack J. Development of linear IgA bullous dermatosis in a patient with psoriasis taking ustekinumab. J Am Acad Dermatol. 2012;67(4):e150\u20131. https:\/\/doi.org\/10.1016\/j.jaad.2011.11.955 .","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"764_CR123","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1001\/archdermatol.2012.586","volume":"148","author":"C Pernet","year":"2012","unstructured":"Pernet C, Guillot B, Bessis D. Eczematous drug eruption after ustekinumab treatment. Arch Dermatol. 2012;148(8):959\u201360. https:\/\/doi.org\/10.1001\/archdermatol.2012.586 .","journal-title":"Arch Dermatol"},{"issue":"8","key":"764_CR124","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1001\/archdermatol.2011.213","volume":"147","author":"J Jung","year":"2011","unstructured":"Jung J, Levin EC, Jarrett R, Lu D, Mann C. Lymphomatoid drug reaction to ustekinumab. Arch Dermatol. 2011;147(8):992\u20133. https:\/\/doi.org\/10.1001\/archdermatol.2011.213 .","journal-title":"Arch Dermatol"},{"issue":"1","key":"764_CR125","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s13555-016-0102-0","volume":"6","author":"B Farahnik","year":"2016","unstructured":"\u2022 Farahnik B, Beroukhim K, Zhu TH, Abrouk M, Nakamura M, Singh R, et al. Ixekizumab for the treatment of psoriasis: a review of phase III trials. Dermatol Ther (Heidelb). 2016;6(1):25\u201337. https:\/\/doi.org\/10.1007\/s13555-016-0102-0 . Pooled efficacy and safety data from three major Phase III trials investigating ixekizumab as a treatment for plaque psoriasis (UNCOVER-1, UNCOVER-2, UNCOVER-3).","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"764_CR126","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa1512711","volume":"375","author":"KB Gordon","year":"2016","unstructured":"Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1512711.","journal-title":"N Engl J Med"},{"issue":"9993","key":"764_CR127","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","volume":"386","author":"CEM Griffiths","year":"2015","unstructured":"Griffiths CEM, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet (London, England). 2015;386(9993):541\u201351. https:\/\/doi.org\/10.1016\/S0140-6736(15)60125-8.","journal-title":"Lancet (London, England)."},{"key":"764_CR128","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2147\/CCID.S111007","volume":"10","author":"T Kazemi","year":"2017","unstructured":"Kazemi T, Farahnik B, Koo J, Beroukhim K. Emerging targeted therapies for plaque psoriasis - impact of ixekizumab. Clin Cosmet Investig Dermatol. 2017;10:133\u20139. https:\/\/doi.org\/10.2147\/CCID.S111007 .","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"1","key":"764_CR129","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1517\/14712598.2016.1121986","volume":"16","author":"B Rothstein","year":"2016","unstructured":"Rothstein B, Gottlieb A. Secukinumab for treating plaque psoriasis. Expert Opin Biol Ther. 2016;16(1):119\u201328. https:\/\/doi.org\/10.1517\/14712598.2016.1121986 .","journal-title":"Expert Opin Biol Ther"},{"key":"764_CR130","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2147\/TCRM.S111107","volume":"13","author":"TL Hanley","year":"2017","unstructured":"Hanley TL, Yiu ZZ. Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab. Ther Clin Risk Manag. 2017;13:315\u201323. https:\/\/doi.org\/10.2147\/TCRM.S111107 .","journal-title":"Ther Clin Risk Manag"},{"issue":"14","key":"764_CR131","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","volume":"373","author":"M Lebwohl","year":"2015","unstructured":"Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1503824.","journal-title":"N Engl J Med"},{"issue":"3","key":"764_CR132","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","volume":"73","author":"D Tha\u00e7i","year":"2015","unstructured":"Tha\u00e7i D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2015.05.013.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"764_CR133","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jaad.2014.02.035","volume":"71","author":"ME Lacouture","year":"2014","unstructured":"Lacouture ME, Wolchok JD, Yosipovitch G, K\u00e4hler KC, Busam KJ, Hauschild A. Ipilimumab in patients with cancer and the management of dermatologic adverse events. J Am Acad Dermatol. 2014;71(1):161\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2014.02.035 .","journal-title":"J Am Acad Dermatol"},{"issue":"5 Suppl","key":"764_CR134","doi-asserted-by":"publisher","first-page":"686","DOI":"10.6004\/jnccn.2015.0204","volume":"13","author":"ME Lacouture","year":"2015","unstructured":"Lacouture ME. Management of dermatologic toxicities. J Natl Compr Canc Netw. 2015;13(5 Suppl):686\u20139. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25995431 . Accessed 3 Dec 2017","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"764_CR135","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","volume":"28","author":"L Khoja","year":"2017","unstructured":"\u2022 Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol Off J Eur Soc Med Oncol. 2017;28(10):2377\u201385. https:\/\/doi.org\/10.1093\/annonc\/mdx286 . A 2017 meta-analysis of 6938 patients in 26 CTLA-4, 17 PD-1, 3 combined CTLA-4 and PD-1, and 2 PD-L1 trials.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"12","key":"764_CR136","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.urolonc.2017.08.005","volume":"35","author":"AW Hahn","year":"2017","unstructured":"Hahn AW, Gill DM, Agarwal N, Maughan BL. PD-1 checkpoint inhibition: toxicities and management. Urol Oncol. 2017;35(12):701\u20137. https:\/\/doi.org\/10.1016\/j.urolonc.2017.08.005 .","journal-title":"Urol Oncol"},{"key":"764_CR137","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ejca.2017.03.026","volume":"81","author":"S Saw","year":"2017","unstructured":"Saw S, Lee HY, Ng QS. Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients. Eur J Cancer. 2017;81:237\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2017.03.026 .","journal-title":"Eur J Cancer"},{"issue":"3","key":"764_CR138","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1016\/j.jaad.2012.12.963","volume":"69","author":"K Minkis","year":"2013","unstructured":"Minkis K, Garden BC, Wu S, Pulitzer MP, Lacouture ME. The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis. J Am Acad Dermatol. 2013;69(3):e121\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2012.12.963 .","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"764_CR139","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1504030.","journal-title":"N Engl J Med"},{"issue":"10","key":"764_CR140","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","volume":"2","author":"CF Friedman","year":"2016","unstructured":"Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016;2(10):1346\u201353. https:\/\/doi.org\/10.1001\/jamaoncol.2016.1051 .","journal-title":"JAMA Oncol"},{"issue":"21","key":"764_CR141","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","volume":"30","author":"JS Weber","year":"2012","unstructured":"Weber JS, K\u00e4hler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21):2691\u20137. https:\/\/doi.org\/10.1200\/JCO.2012.41.6750 .","journal-title":"J Clin Oncol"},{"issue":"26","key":"764_CR142","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1503093.","journal-title":"N Engl J Med"},{"issue":"7","key":"764_CR143","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","volume":"33","author":"H-E Teulings","year":"2015","unstructured":"Teulings H-E, Limpens J, Jansen SN, Zwinderman AH, Reitsma JB, Spuls PI, et al. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol. 2015;33(7):773\u201381. https:\/\/doi.org\/10.1200\/JCO.2014.57.4756 .","journal-title":"J Clin Oncol"},{"issue":"9","key":"764_CR144","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1001\/jamaoncol.2015.2274","volume":"1","author":"JA Lo","year":"2015","unstructured":"Lo JA, Fisher DE, Flaherty KT. Prognostic significance of cutaneous adverse events associated with pembrolizumab therapy. JAMA Oncol. 2015;1(9):1340\u20131. https:\/\/doi.org\/10.1001\/jamaoncol.2015.2274 .","journal-title":"JAMA Oncol"},{"issue":"1","key":"764_CR145","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","volume":"152","author":"C Hua","year":"2016","unstructured":"Hua C, Boussemart L, Mateus C, Routier E, Boutros C, Cazenave H, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol. 2016;152(1):45\u201351. https:\/\/doi.org\/10.1001\/jamadermatol.2015.2707.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"764_CR146","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/CMR.0000000000000155","volume":"25","author":"G Carlos","year":"2015","unstructured":"Carlos G, Anforth R, Chou S, Clements A, Fernandez-Pe\u00f1as P. A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab. Melanoma Res. 2015;25(3):265\u20138. https:\/\/doi.org\/10.1097\/CMR.0000000000000155 .","journal-title":"Melanoma Res"},{"issue":"6","key":"764_CR147","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/CMR.0000000000000017","volume":"23","author":"S Pintova","year":"2013","unstructured":"Pintova S, Sidhu H, Friedlander PA, Holcombe RF. Sweet\u2019s syndrome in a patient with metastatic melanoma after ipilimumab therapy. Melanoma Res. 2013;23(6):498\u2013501. https:\/\/doi.org\/10.1097\/CMR.0000000000000017 .","journal-title":"Melanoma Res"},{"issue":"1","key":"764_CR148","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1158\/2326-6066.CIR-14-0134","volume":"3","author":"RW Joseph","year":"2015","unstructured":"Joseph RW, Cappel M, Goedjen B, Gordon M, Kirsch B, Gilstrap C, et al. Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy. Cancer Immunol Res. 2015;3(1):18\u201322. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0134.","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"764_CR149","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa1314768","volume":"371","author":"LA Beck","year":"2014","unstructured":"Beck LA, Thaci D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1314768 .","journal-title":"N Engl J Med"},{"issue":"10013","key":"764_CR150","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","volume":"387","author":"D Tha\u00e7i","year":"2016","unstructured":"Tha\u00e7i D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet (London, England). 2016;387(10013):40\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(15)00388-8 .","journal-title":"Lancet (London, England)."},{"issue":"10039","key":"764_CR151","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","volume":"388","author":"S Wenzel","year":"2016","unstructured":"Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet (London, England). 2016;388(10039):31\u201344. https:\/\/doi.org\/10.1016\/S0140-6736(16)30307-5.","journal-title":"Lancet (London, England)"},{"issue":"5","key":"764_CR152","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1001\/jama.2015.19330","volume":"315","author":"C Bachert","year":"2016","unstructured":"Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA. 2016;315(5):469\u201379. https:\/\/doi.org\/10.1001\/jama.2015.19330.","journal-title":"JAMA"},{"issue":"10086","key":"764_CR153","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet (London, England). 2017;389(10086):2287\u2013303. https:\/\/doi.org\/10.1016\/S0140-6736(17)31191-1 .","journal-title":"Lancet (London, England)"},{"issue":"11","key":"764_CR154","doi-asserted-by":"publisher","first-page":"e0166833","DOI":"10.1371\/journal.pone.0166833","volume":"11","author":"F-P Wang","year":"2016","unstructured":"Wang F-P, Liu T, Lan Z, Li S-Y, Mao H. Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: a systematic review and meta-analysis. Loukides S, ed. PLoS One. 2016;11(11):e0166833. https:\/\/doi.org\/10.1371\/journal.pone.0166833.","journal-title":"PLoS One"},{"issue":"3","key":"764_CR155","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1080\/14740338.2017.1286327","volume":"16","author":"E Leung","year":"2017","unstructured":"Leung E, Al Efraij K, FitzGerald JM. The safety of mepolizumab for the treatment of asthma. Expert Opin Drug Saf. 2017;16(3):397\u2013404. https:\/\/doi.org\/10.1080\/14740338.2017.1286327 .","journal-title":"Expert Opin Drug Saf"},{"issue":"9","key":"764_CR156","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1111\/j.1600-6143.2012.04127.x","volume":"12","author":"F Vincenti","year":"2012","unstructured":"Vincenti F, Tedesco Silva H, Busque S, O\u2019Connell P, Friedewald J, Cibrik D, et al. Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year. Am J Transplant. 2012;12(9):2446\u201356. https:\/\/doi.org\/10.1111\/j.1600-6143.2012.04127.x.","journal-title":"Am J Transplant"},{"issue":"4","key":"764_CR157","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/art.33419","volume":"64","author":"JM Kremer","year":"2012","unstructured":"Kremer JM, Cohen S, Wilkinson BE, Connell CA, French JL, Gomez-Reino J, et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum. 2012;64(4):970\u201381. https:\/\/doi.org\/10.1002\/art.33419.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"764_CR158","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s10067-007-0743-6","volume":"27","author":"A Golmia","year":"2008","unstructured":"Golmia A, Grinblat B, Finger E, Klieman C, Assir F, Scheinberg M. The development of erythema elevatum diutinum in a patient with juvenile idiopathic arthritis under treatment with abatacept. Clin Rheumatol. 2008;27(1):105\u20136. https:\/\/doi.org\/10.1007\/s10067-007-0743-6.","journal-title":"Clin Rheumatol"},{"issue":"3","key":"764_CR159","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/ajd.12185","volume":"55","author":"SM Tiwari","year":"2014","unstructured":"Tiwari SM, Wood BA, Skender-Kalnenas T, Cook N. A case of abatacept associated neutrophilic dermatosis and a review of the literature. Australas J Dermatol. 2014;55(3):214\u20137. https:\/\/doi.org\/10.1111\/ajd.12185 .","journal-title":"Australas J Dermatol"},{"issue":"12","key":"764_CR160","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.annder.2012.09.005","volume":"139","author":"J-L Schmutz","year":"2012","unstructured":"Schmutz J-L, Trechot P. Paradoxical psoriasiform eruption due to abatacept (ORENCIA(\u00ae)). Ann Dermatol Venereol. 2012;139(12):871\u20132. https:\/\/doi.org\/10.1016\/j.annder.2012.09.005.","journal-title":"Ann Dermatol Venereol"},{"issue":"1","key":"764_CR161","doi-asserted-by":"publisher","first-page":"92","DOI":"10.4103\/0378-6323.125502","volume":"80","author":"E Conde-Montero","year":"2014","unstructured":"Conde-Montero E, Baniandr\u00e9s-Rodr\u00edguez O, Mendoza-Cembranos MD, Horcajada-Reales C, Su\u00e1rez-Fern\u00e1ndez R. Psoriasiform reactions during treatment with abatacept. Indian J Dermatol Venereol Leprol. 2014;80(1):92\u20133. https:\/\/doi.org\/10.4103\/0378-6323.125502 .","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"9","key":"764_CR162","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899\u2013910. https:\/\/doi.org\/10.1056\/NEJMoa044397 .","journal-title":"N Engl J Med"},{"issue":"2","key":"764_CR163","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.farma.2010.02.003","volume":"35","author":"MJ Fern\u00e1ndez-Meg\u00eda","year":"2011","unstructured":"Fern\u00e1ndez-Meg\u00eda MJ, Casanova B, Magraner MJ, Font-Noguera I, Poveda-Andr\u00e9s JL. Assessment of the effectiveness and safety of natalizumab for treating relapsing-remitting multiple sclerosis. Farm Hosp. 2011;35(2):75\u20139. https:\/\/doi.org\/10.1016\/j.farma.2010.02.003 .","journal-title":"Farm Hosp"}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11882-018-0764-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-018-0764-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-018-0764-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T05:36:34Z","timestamp":1693546594000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11882-018-0764-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":163,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["764"],"URL":"https:\/\/doi.org\/10.1007\/s11882-018-0764-z","relation":{},"ISSN":["1529-7322","1534-6315"],"issn-type":[{"value":"1529-7322","type":"print"},{"value":"1534-6315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"21 February 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare no conflicts of interest relevant to this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"12"}}